epoetin alfa

Generic Name: epoetin alfa

Clinical Trials

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Phase 3

Terminated

Conditions: Anemia
Lung Cancer
Non-Small-Cell Lung Carcinoma

First Posted Date: 2006-04-03

Last Posted Date: 2024-04-02

Lead Sponsor: Ontario Clinical Oncology Group (OCOG)

Target Recruit Count: 70

Registration Number: NCT00310232

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
St. John Regional Hospital, St. John, New Brunswick, Canada
🇨🇦
Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada

and more 12 locations

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Phase 2

Completed

Conditions: Anemia
Chronic Renal Insufficiency

First Posted Date: 2006-03-28

Last Posted Date: 2011-05-19

Lead Sponsor: Ortho Biotech Products, L.P.

Target Recruit Count: 519

Registration Number: NCT00307814

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Phase 2

Terminated

Conditions: Anemia
Cancer
Epoetin Alfa

First Posted Date: 2006-03-23

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 61

Registration Number: NCT00306267

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Phase 4

Completed

Conditions: Anemia
Neoplasm

First Posted Date: 2006-01-30

Last Posted Date: 2011-01-14

Lead Sponsor: Janssen-Cilag B.V.

Target Recruit Count: 316

Registration Number: NCT00283465

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Phase 2

Completed

Conditions: Anemia
Blood Transfusion
Orthopedic Procedures

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 1

Registration Number: NCT00270036

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Phase 3

Completed

Conditions: Carcinoma, Small Cell Lung
Anemia
Multiple Myeloma
Esophagus Cancer
Neoplasm
Lymphoma
Ovarian Cancer
Breast Cancer
Prostate Cancer

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 201

Registration Number: NCT00270166

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2

Completed

Conditions: Neoplasms
Anemia

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 72

Registration Number: NCT00269997

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Phase 2

Completed

Conditions: Anemia
Acquired Immunodeficiency Syndrome

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 60

Registration Number: NCT00269945

A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.

Phase 3

Completed

Conditions: Anemia
Blood Transfusion
Orthopedic Procedures

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 316

Registration Number: NCT00270088

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Anemia
Leukemia, Lymphocytic, Chronic
Leukemia, Lymphocytic
Cancer
Neoplasms
Quality of Life

First Posted Date: 2005-12-26

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 195

Registration Number: NCT00270049

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.